Epstein Secrets

From: ' To: Lesley Groff Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:17:36 +0000 Lesley please forward to Jeffrey rs Rony

From: ' To: Lesley Groff Subject: Fwd: FOURIER: Significant LDL Reductio

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright C' 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communicatio

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:18:31 +0000

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Sub

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright @ 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication

From: Lesley Groff To: "Dr. Rony + Catherine Shimony" Subject: Re: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:18:21 +0000 will d

From: Lesley Groff To: "Dr. Rony + Catherine Shimony" Subject: R

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright O 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication